[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 647, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 60, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 2562753, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "age": 48, "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher  Williams", "age": 44, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthias  Will M.D.", "age": 51, "title": "Senior VP & Chief Development Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 52, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 54, "title": "Senior VP, CFO & Principal Accounting Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 59, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 68, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "age": 59, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.29, "open": 1.29, "dayLow": 1.29, "dayHigh": 1.36, "regularMarketPreviousClose": 1.29, "regularMarketOpen": 1.29, "regularMarketDayLow": 1.29, "regularMarketDayHigh": 1.36, "payoutRatio": 0.0, "beta": 1.762, "forwardPE": -1.8219178, "volume": 2826408, "regularMarketVolume": 2826408, "averageVolume": 1867490, "averageVolume10days": 2735650, "averageDailyVolume10Day": 2735650, "bid": 1.29, "ask": 1.34, "bidSize": 30, "askSize": 30, "marketCap": 353967520, "fiftyTwoWeekLow": 1.105, "fiftyTwoWeekHigh": 5.0, "priceToSalesTrailing12Months": 39.28171, "fiftyDayAverage": 1.5123, "twoHundredDayAverage": 2.770575, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 145988304, "profitMargins": 0.0, "floatShares": 138093066, "sharesOutstanding": 266140992, "sharesShort": 10449231, "sharesShortPriorMonth": 9910212, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.039300002, "heldPercentInsiders": 0.18086, "heldPercentInstitutions": 0.86333, "shortRatio": 4.63, "shortPercentOfFloat": 0.0517, "impliedSharesOutstanding": 266140992, "bookValue": 1.394, "priceToBook": 0.9540889, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -238132992, "trailingEps": -0.88, "forwardEps": -0.73, "enterpriseToRevenue": 16.201, "enterpriseToEbitda": -0.563, "52WeekChange": -0.67910445, "SandP52WeekChange": 0.11469197, "quoteType": "EQUITY", "currentPrice": 1.33, "targetHighPrice": 14.0, "targetLowPrice": 5.7, "targetMeanPrice": 9.96667, "targetMedianPrice": 10.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 516575008, "totalCashPerShare": 1.941, "ebitda": -259430000, "totalDebt": 308615008, "quickRatio": 7.755, "currentRatio": 9.244, "totalRevenue": 9011000, "debtToEquity": 83.16, "revenuePerShare": 0.034, "returnOnAssets": -0.20275, "returnOnEquity": -0.49967998, "grossProfits": -149960000, "revenueGrowth": -0.11, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -7.2630796, "financialCurrency": "USD", "symbol": "AUTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "postMarketChangePercent": 1.50376, "postMarketPrice": 1.35, "postMarketChange": 0.02, "regularMarketChange": 0.04000008, "regularMarketDayRange": "1.29 - 1.36", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1867490, "fiftyTwoWeekLowChange": 0.22500002, "fiftyTwoWeekLowChangePercent": 0.20361993, "fiftyTwoWeekRange": "1.105 - 5.0", "fiftyTwoWeekHighChange": -3.67, "fiftyTwoWeekHighChangePercent": -0.734, "fiftyTwoWeekChangePercent": -67.910446, "earningsTimestamp": 1746702002, "earningsTimestampStart": 1754656200, "earningsTimestampEnd": 1755865800, "earningsCallTimestampStart": 1746707400, "earningsCallTimestampEnd": 1746707400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.88, "epsForward": -0.73, "epsCurrentYear": -0.93788, "priceEpsCurrentYear": -1.4180919, "fiftyDayAverageChange": -0.18229997, "fiftyDayAverageChangePercent": -0.12054484, "twoHundredDayAverageChange": -1.440575, "twoHundredDayAverageChangePercent": -0.5199552, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "postMarketTime": 1747439426, "regularMarketTime": 1747425601, "exchange": "NMS", "messageBoardId": "finmb_562879769", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.1007814, "regularMarketPrice": 1.33, "marketState": "CLOSED", "corporateActions": [], "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1529674200000, "displayName": "Autolus Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]